Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

788
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
788
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Bipolar Disorder01:30

Bipolar Disorder

1.4K
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
1.4K
Drug Therapy01:28

Drug Therapy

442
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
442
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

693
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
693
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proposal for Circadian Rhythms and Their Behavioral Outputs as Biomarkers in <i>DSM-6</i>: Response to Cuthbert et al.

The American journal of psychiatry·2026
Same author

Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Mu-Opioid Signaling Engagement as a Candidate Maintenance Mechanism for Prolonging Ketamine's Antisuicidal Effects.

The American journal of psychiatry·2026
Same author

Major depressive disorder is associated with reduced intrinsic connectivity between the bed nucleus of the stria terminalis and ventral striatum.

Journal of psychiatry & neuroscience : JPN·2026
Same author

Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis.

JAMA psychiatry·2026
Same author

Mechanistic Underpinnings of Emotional Face Processing in Suicide Risk: Exploring the Moderating Effects of Cortisol on Neural Parameters Using Magnetoencephalography.

Psychiatric research and clinical practice·2026

Related Experiment Video

Updated: Apr 23, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K

Potential novel therapeutics for bipolar disorders.

Rodrigo Machado-Vieira1, Husseini K Manji, Carlos A Zarate

  • 1Experimental Therapeutics, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Mark O. Hatfield CRC, Unit 7 SE, Rm. 7-3445, Bethesda, MD, 20892, USA, machadovieirar@mail.nih.gov.

Current Topics in Behavioral Neurosciences
|September 20, 2014
PubMed
Summary

Novel treatments for bipolar disorder (BPD) are needed as current therapies are insufficient. This review explores potential new drug targets and compounds for BPD, offering hope for improved patient outcomes.

More Related Videos

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

1.0K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.8K

Related Experiment Videos

Last Updated: Apr 23, 2026

Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.6K
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

1.0K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Bipolar disorder (BPD) is a severe mood disorder with persistent symptoms and functional impairment despite current treatments.
  • Many patients do not achieve adequate symptom control or remission with existing pharmacological interventions.

Purpose of the Study:

  • To review potential novel therapeutic targets and compounds for bipolar disorder (BPD).
  • To explore emerging pharmacological avenues beyond current treatment standards.

Main Methods:

  • Literature review of preclinical and clinical studies on novel BPD targets.
  • Analysis of compounds targeting specific neurotransmitter systems and intracellular pathways.
  • Examination of agents with multi-target effects.

Main Results:

  • Several systems show promise, including dynorphin, glutamatergic, purinergic, cholinergic, oxidative stress, and melatonergic systems.
  • Intracellular signaling cascades like GSK-3 and PKC, and the arachidonic acid cascade are potential targets.
  • Agents like modafinil and Uridine RG2417 affecting multiple targets warrant further investigation.

Conclusions:

  • Further research into these novel targets and compounds could lead to more effective treatments for bipolar disorder (BPD).
  • Understanding these pathways may enhance therapeutic strategies for this debilitating condition.